Boston Neuro Research is conducting a comprehensive study to better understand and develop treatments for Alzheimer’s disease, a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. This study aims to explore new therapeutic approaches and gather data to improve the quality of life for those affected by Alzheimer’s.

INCLUSIONS:

Participants eligible for the Alzheimer’s study at Boston Neuro Research must meet certain criteria to ensure the accuracy and relevance of the research findings. The inclusions are as follows:

1. Diagnosis: Individuals must have a clinical diagnosis of mild to moderate Alzheimer’s disease.
2. Age: Participants should be aged 50 to 85 years.
3. Health Status: Stable medical conditions unrelated to Alzheimer’s that do not interfere with study procedures.
4. Caregiver: A reliable caregiver must be available to assist with participation in the study.
5. Informed Consent: Participants and caregivers must provide informed consent to join the study.

EXCLUSIONS:

Certain factors may disqualify individuals from participating in the Boston Neuro Research Alzheimer’s study. The exclusions are designed to maintain the safety and integrity of the research. The exclusions include:

1. Severe Alzheimer’s Disease: Individuals with advanced Alzheimer’s disease.
2. Other Neurological Disorders: Presence of other significant neurological disorders, such as Parkinson’s disease or stroke.
3. Unstable Medical Conditions: Uncontrolled chronic illnesses, such as severe cardiovascular disease or diabetes.
4. Recent Participation: Involvement in other clinical trials within the past 30 days.
5. Psychiatric Disorders: Severe psychiatric conditions that could interfere with the study, such as major depression or schizophrenia.

MEDICATIONS:

Participants in the Boston Neuro Research Alzheimer’s study will be administered specific medications designed to target the underlying causes and symptoms of the disease. The medications include:

1. Cholinesterase Inhibitors: Drugs such as Donepezil, Rivastigmine, and Galantamine, which help increase levels of acetylcholine in the brain, potentially improving memory and cognitive function.
2. NMDA Receptor Antagonists: Memantine is used to regulate glutamate activity in the brain, which can help slow the progression of symptoms in moderate to severe Alzheimer’s cases.
3. Investigational Drugs: New medications and compounds that are currently being tested for their efficacy and safety in treating Alzheimer’s disease.
4. Adjunct Therapies: Additional treatments such as anti-inflammatory drugs, antioxidants, and lifestyle interventions that may complement primary medication effects.

This study at Boston Neuro Research represents a vital step forward in the fight against Alzheimer’s disease, offering hope for improved treatments and a better understanding of this debilitating condition.